EMA Approves Loba Biotech as New Manufacturing Site for Pegasys, Restoring European Supply
• The European Medicines Agency has approved pharma&'s manufacturing subsidiary Loba biotech as a production site for Pegasys (peginterferon alfa-2a), enabling replenishment of supplies across Europe.
• pharma& acquired global rights to Pegasys in 2021 after Roche announced discontinuation, investing significantly in Loba biotech's manufacturing capabilities to meet increased patient demand.
• The approval represents a critical step in pharma&'s mission to ensure continuous availability of essential medicines, with efforts underway to enhance Pegasys accessibility in the US and other regions.
© Copyright 2025. All Rights Reserved by MedPath